IP Library Granted Patent US 8,383,335
Granted Patent B2
US 8,383,335 · App. 13/114,289 · Granted Feb 26, 2013

Method for diagnosis and monitoring of viral infection by analysis of viral transrenal nucleic acids in urine

Inventors: Hovsep Melkonyan (Princeton, NJ); Angela Cannas (Arbus, IT); Louis David Tomei (Genazzano, IT); Samuil R. Umansky (Princeton, NJ)
Assignee: Trovagene, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,383,335
App. No.
13/114,289
Granted
Feb 26, 2013
Kind
B2
Abstract

The present invention relates to methods for diagnosis or monitoring of viral infection by detecting the presence of transrenal viral nucleic acids or nucleic acids of viral origin in urine sample, with or without isolation of nucleic acids from a urine sample. The analysis of the nucleic acids is performed through hybridization of the nucleic acids with specific probes, or through a chain amplification reaction with specific primers. The methods are applicable to all viral pathogenic agents, including RNA, DNA, episomal, or integrated viruses.

Claims (31)

1. A method for diagnosing a virus infection in a subject, comprising

a) obtaining a urine sample from a subject;

b) separating a soluble fraction of said urine sample; and

c) detecting the presence of a cell-free virus nucleic acid in said soluble fraction of said urine sample, wherein said nucleic acid is less than about 300 bp in length, wherein said detecting is performed by a method selected from the group consisting of PCR, nested PCR, SSCP, LCR, and SDA, using a primer set comprising

at least one forward primer selected from the group consisting of SEQ ID NOs: 1 and 3 and at least one reverse primer selected from the group consisting of SEQ ID NOs: 2 and 4, or

a forward primer of SEQ ID NO: 5 and at least one reverse primer selected from the group consisting of SEQ ID NOs: 6 and 7, or

a forward primer of SEQ ID NO: 11 and a reverse primer of SEQ ID NO: 10,

wherein the presence of said nucleic acid diagnoses a viral infection.

2. The method of claim 1 , further comprising the step of quantifying the nucleic acid.

3. The method of claim 1 , wherein the subject is a mammal.

4. The method of claim 3 , wherein the mammal is a human.

5. A method for diagnosing a virus infection in a subject, comprising

a) obtaining a urine sample from a subject;

b) separating a soluble fraction of said urine sample; and

c) detecting the presence of a cell-free virus nucleic acid in said soluble fraction of said urine sample by a method selected from the group consisting of PCR, nested PCR, SSCP, LCR, and SDA, using a forward primer of SEQ ID NO: 5 and a reverse primer of SEQ ID NO: 8, wherein the presence of said nucleic acid diagnoses a viral infection.

6. The method of claim 5 , further comprising the step of quantifying the nucleic acid.

7. The method of claim 5 , wherein the subject is a mammal.

8. The method of claim 7 , wherein the mammal is a human.

9. A method for diagnosing a virus infection in a subject, comprising

a) obtaining a urine sample from a subject;

b) separating a soluble fraction of said urine sample; and

c) detecting the presence of a cell-free virus nucleic acid in said soluble fraction of said urine sample by a method selected from the group consisting of PCR, nested PCR, SSCP, LCR, and SDA, using a forward primer of SEQ ID NO: 9 and a reverse primer of SEQ ID NO: 10, wherein the presence of said nucleic acid diagnoses a viral infection.

10. The method of claim 9 , further comprising the step of quantifying the nucleic acid.

11. The method of claim 9 , wherein the subject is a mammal.

12. The method of claim 11 , wherein the mammal is a human.

13. The method of claim 2 , wherein said primer set comprises at least one forward primer selected from SEQ ID NOs: 1 and 3 and at least one reverse primer selected from SEQ ID NOs: 2 and 4.

14. The method of claim 4 , wherein said primer set comprises at least one forward primer selected from SEQ ID NOs: 1 and 3 and at least one reverse primer selected from SEQ ID NOs: 2 and 4.

15. The method of claim 2 , wherein said primer set comprises a forward primer of SEQ ID NO: 5 and at least one reverse primer selected from the group consisting of SEQ ID NOs: 6 and 7.

16. The method of claim 4 , wherein said primer set comprises a forward primer of SEQ ID NO: 5 and at least one reverse primer selected from the group consisting of SEQ ID NOs: 6 and 7.

17. The method of claim 2 , wherein said primer set comprises a forward primer of SEQ ID NO: 11 and a reverse primer of SEQ ID NO: 10.

18. The method of claim 4 , wherein said primer set comprises a forward primer of SEQ ID NO: 11 and a reverse primer of SEQ ID NO: 10.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 21, 2014
From: MELKONYAN, HOVSEP; CANNAS, ANGELA; TOMEI, LOUIS DAVID; UMANSKY, SAMUIL R.
To: INSTITUTO NAZIONALE PER LE MALATTIE INFETTIVE IRCCS LAZZARO SPALLANZANI
Reel/Frame 033997/0130 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 21, 2014
From: INSTITUTO NAZIONALE PER LE MALATTIE INFETTIVE IRCCS LAZZARO SPALLANZANI
To: XENOMICS, INC.
Reel/Frame 033997/0223 →
MERGER Recorded Oct 21, 2014
From: XENOMICS, INC.
To: TROVAGENE, INC.
Reel/Frame 033997/0272 →
Priority Claims (1)
IT RM2005A0067 · Feb 17, 2005 · national
Continuity (2)
Continuation 11137935 · May 25, 2005
Related Publication 20120021404A1 · Jan 26, 2012